SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Pure Green, LLC, (Nasdaq: PURE) Trading at $3.04, Up $1.19. Today announced that PureGreen24, powered by PURE Bioscience’s patented silver dihydrogen citrate (SDC) antimicrobial, meets the recommendations by the United States Centers for Disease Control (CDC) for infection control for care of patients with confirmed or suspected Swine Influenza A (H1N1) virus in both home and healthcare settings.
According to the CDC, human transmission of flu occurs through coughing or sneezing of people infected with the influenza virus. People may become infected by touching something with viruses on it and then touching their mouths or noses.
What They Do: Pure Green, LLC is the international distributor of PureGreen24 disinfectant and deodorizer. Pure Green is dedicated to reducing health risks caused by exposure to pathogens without endangering humans and animals during the disinfecting process. PureGreen24 kills MRSA and Staph, yet also kills common household germs and provides 24-hour effectiveness against standard bacteria.
Syntel, Inc. (Nasdaq: SYNT) Trading at $28.99, Up $5.78. Today announced financial results for the first quarter, ended March 31, 2009. Syntel's revenue for the first quarter decreased two percent to $96.4 million, compared to $98.5 million in the prior-year period and eight percent sequentially from $104.7 million in the fourth quarter of 2008. Revenue was adversely impacted by currency headwinds, reduced pricing and reductions in discretionary spending. During the first quarter, Applications Outsourcing accounted for 70 percent of total revenue, with Knowledge Process Outsourcing (KPO) at 19 percent, e-Business contributing nine percent and Team Sourcing at two percent.
Net income for the first quarter was $27.3 million or $0.66 per diluted share, compared to $20.4 million or $0.49 per diluted share in the prior-year period and net income of $26.7 million or $0.64 per diluted share in the fourth quarter of 2008.
What They Do: Syntel is a leading global provider of integrated information technology and Knowledge Process Outsourcing (KPO) solutions spanning the entire lifecycle of business and information systems and processes.
Human Genome Sciences (Nasdaq: HGSI) Trading at $1.53, Up $0.23. Announced Saturday the final results of two pivotal Phase 3 trials demonstrate that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in the treatment of patients with chronic hepatitis C. The Phase 3 results were the subject of two late-breaker oral presentations today in Copenhagen at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
What They Do: The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
